FARON PHARMA(FARN.UK)

133.00+0.000.00%

行情数据延迟15分钟

    • 最新
    • 推荐
      empty
      暂无内容
      • 公司概况

        公司名称
        FARON PHARMA
        所属市场
        LSE
        成立日期
        - -
        员工人数
        - -
        办公地址
        - -
        邮政编码
        - -
        联系电话
        - -
        联系传真
        - -
        公司概况
        Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.
        • 分时
        • 5日
        最高
        133.00
        今开
        133.00
        量比
        0.00
        最低
        133.00
        昨收
        133.00
        换手率
        0.00%
         
         
         
         

        热议股票